Glycobiology is the study of carbohydrates and carbohydrate-containing biomolecules in biological processes. This study is used in diagnostics, drug discovery research, immunology, oncology, and various other applications. Glycobiology products are widely used for analysis of cell surface markers, which can act as diagnostic or therapeutic targets.
The global glycobiology market is expected to reach USD 1,211.4 million by 2021 from USD 649.5 million in 2016, at a CAGR of 13.3%.
Increasing funding for proteomics & glycomics research and growing R&D expenditure drives the global glycobiology market
The growing demand for remedial treatments for life-threatening diseases, such as cancer, has driven the pace of pharmaceutical and biotechnological R&D as well as overall investments made in this sector. Both glycomics (being the study of glycans) and proteomics (being the study of proteins, and holding a prominent place in glycome R&D) are research-driven sectors. Moreover, glycomic biomarkers are finding significant applications in drug development and diagnostics for such diseases. As a result, the growing availability of funding for these two sectors is expected to aid the growth of the glycobiology market, in the coming years.
Major Glycobiology Market Developments
- In November 2016, ProZyme Inc. (U.S.) launched the Gly-Q glycan analysis system, an integrated platform for high-throughput, user-friendly glycoanalysis. With this system, biopharma companies can determine the glycan profiles of their samples faster, while reducing overall costs. It will benefit researchers running glycomic analysis of large datasets, including clinical samples.
- In December 2015, Waters Corporation (U.S.) announced the launch of the GlycoWorks RapiFluor-MS N-Glycan kit in a 24-sample format. The new format processes 24 samples, 8 at a time. It helps laboratories transform their monoclonal antibody glycoprofiling methodology
- In November 2015, Merck KGaA (Germany) acquired Sigma-Aldrich (US) for an approximate value of USD 17 billion. This acquisition helped the company expand its business in various geographies and enhanced its product portfolio, including life science and diagnostic.
- In February 2014, Thermo Fisher Scientific acquired Life Technologies for an approximate value of USD 13.6 billion, plus the assumption of USD 1.5 billion in net debt. This acquisition helped the company expand its business in various geographies and enhanced its product portfolio
Glycomics is a promising approach to biomarker discovery and validation. The development of various separation techniques coupled with the advanced structure determination capabilities of this field makes possible the separation and identification of thousands of glycans from complex mixtures. Biomarker identification presents significant opportunities for the glycobiology market. Glycomics also has a wide range of applications in drug development and enhancement. Glycomics products such as enzymes, kits, and reagents are often used in investigating the role of sugars in the development and progression of diseases like cancer, Alzheimer’s, Parkinson’s, and various infectious diseases like herpes and AIDS.
There is a high degree of rivalry amongst glycobiology market players, which keeps the market highly competitive. The top players in glycomics market are large and well-established players, who enjoy strong brand loyalty. New entrants in this glycobiology market have to compete with existing players and differentiate themselves and their product offerings; this will require high capital, R&D, and manufacturing investments. Additionally, R&D in this glycobiology market is a very time-consuming process and needs heavy investments in terms of human efforts and time as well. These factors are restraining the entry of new players, and as such are expected to restrain the growth potential of this glycobiology market.